Vyne Therapeutics Capital Expenditures Over Time
| VYNE Stock | USD 3.17 0.06 1.86% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vyne Therapeutics Performance and Vyne Therapeutics Correlation. Vyne |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share 0.016 | Quarterly Revenue Growth 0.467 | Return On Assets (0.35) | Return On Equity (0.60) |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capital Expenditures Analysis
Compare Vyne Therapeutics and related stocks such as Akari Therapeutics PLC, Salarius Pharmaceuticals, and Axcella Health Capital Expenditures Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKTX | 0.0 | 0.0 | 4 K | 0.0 | 57 K | 10.6 K | 54.8 K | 36.9 K | 36.9 K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| SLRX | 265.6 K | 265.6 K | 265.6 K | 265.6 K | 265.6 K | 265.6 K | 559.4 K | 113.5 K | 2.6 K | 2.6 K | 2.6 K | 0.0 | 1.5 M | 3.0 | 2.85 |
| HSTO | 3.9 K | 3.9 K | 3.9 K | 3.9 K | 242.7 K | 88.5 K | 109.6 K | 25.5 K | 66 K | 152 K | 49 K | 241 K | 216 K | 0.0 | 0.0 |
| SABS | 608.7 K | 608.7 K | 608.7 K | 608.7 K | 608.7 K | 608.7 K | 608.7 K | 608.7 K | 608.7 K | 608.7 K | 12.7 M | 10.9 M | 10.9 M | 197.2 K | 187.3 K |
| GOVX | 81.2 K | 11.9 K | 0.0 | 86.6 K | 35.5 K | 15.8 K | 15.8 M | 4.3 K | 7.6 K | 7.6 K | 156.8 K | 47.7 K | 134.3 K | 48.9 K | 46.5 K |
| UNCY | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 2 K | 12 K | 17.3 K |
| PULM | 0.0 | 0.0 | 4 K | 0.0 | 156 K | 266 K | 455 K | 74 K | 19 K | 58 K | 281 K | 144 K | 86 K | 676 K | 709.8 K |
| CDTX | 0.0 | 0.0 | 0.0 | 0.0 | 991 K | 1.2 M | 401 K | 306 K | 177 K | 35 K | 186 K | 41 K | 118 K | 505 K | 285.8 K |
| PHIO | 59 K | 59 K | 15 K | 78 K | 95 K | 57 K | 4 K | 203 K | 5 K | 72 K | 19 K | 51 K | 121 K | 5 K | 4.8 K |
| KRON | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 2.9 M | 9.6 M | 4.3 M | 577 K | 679 K | 645 K |
| VCYT | 276 K | 276 K | 1.5 M | 1.3 M | 2 M | 6.2 M | 4.2 M | 1.8 M | 1.9 M | 2.8 M | 2.8 M | 5.4 M | 8.5 M | 10 M | 10.5 M |
| LGVN | 211.7 K | 211.7 K | 211.7 K | 211.7 K | 211.7 K | 211.7 K | 211.7 K | 211.7 K | 211.7 K | 125 K | 261.5 K | 1.3 M | 856 K | 694 K | 634 K |
| LYRA | 37 K | 37 K | 37 K | 37 K | 37 K | 37 K | 37 K | 37 K | 37 K | 211 K | 1.8 M | 3.4 M | 164 K | 1 M | 1.2 M |
| REVB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 582 K | 582 K | 804 K | 861 K | 526 K | 132 K | 132 K | 0.0 | 4.0 | 3.8 |
| ZURA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12 M | 8 M | 7.3 M |
| ZVSA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 1.05 |
Vyne Therapeutics and related stocks such as Akari Therapeutics PLC, Salarius Pharmaceuticals, and Axcella Health Capital Expenditures description
Capital Expenditures are funds used by Vyne Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Vyne Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.My Equities
My Current Equities and Potential Positions
| Vyne Therapeutics | VYNE |
| Classification | Pharmaceutical Products |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.17
Check out Vyne Therapeutics Performance and Vyne Therapeutics Correlation. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Vyne Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.